Introduction
Glycogen storage disease type IIIA (GSD IIIA, OMIM 232400) is caused by mutations in the amyloglucosidase gene (AGL). Molecular genetic diagnosis is laborious because the AGL gene with its coding sequence of 7.0 kb is relatively large and none of the approximately 30 AGL mutations detected to date is particularly frequent. 1 Besides an unusually high frequency among North African Jews in Israel, 2 a cluster of GSD IIIA cases has long been known to exist in the Faroe Islands. 3 The population of this small archipelago in the North Atlantic (78W, 628N) has its roots in the colonisation by Norwegians in the eighth century and throughout the Viking Age. Here we report the molecular basis of the Faroese GSD IIIA cases together with the results of our calculation of prevalence numbers demonstrating that the Faroe Islands have the highest prevalence of GSD IIIA world-wide. 
Materials and methods

Subjects
Molecular studies
Genomic DNA was extracted from leukocytes according to standard protocols; for the preparation from dried blood samples the E.Z.N.A.
1
-Tissue DNA kit (Peqlab Biotechnologie, Erlangen, Germany) was used. Sense (sn) and antisense (asn) primer sequences for PCR amplification of exons 3 to 35 and the flanking intronic sequences of the AGL gene were chosen from the published gene sequence (GenBank accession numbers AB035420-AB035443). 4 Primer sequences used for the detection of mutations and polymorphisms reported in this paper are given in Table 1 . Mutation analysis was performed according to the Thermo-Sequenase 1 cycle sequencing kit (Amersham/Buchler, Wenden, Germany) using 33 P-radiolabelled terminators. Mutations and polymorphisms were confirmed by restrictions fragment length (RFL) analysis, eventually after PCR with a mismatch primer and digestion with the respective enzyme ( Table 1) .
Results
Mutation analysis
The novel nonsense mutation c.1222 C4T (R408X) of the AGL gene was found in the homozygous state in all six GSD IIIA patients from the Faroe Islands (Figure 1a,b) . This allele was also found in another two compound heterozygous Caucasian GSD IIIA patients resident in the UK and the US, respectively ( Table 2 ). All Faroese patients were homozygous for the same haplotype defined by five intragenic polymorphisms (Table 1) , two of which (IVS 8 ± 18 G*A, IVS 23 ± 21 T*A) have not been previously reported. Results of haplotype analysis in the two compound heterozygotes who did not live in the Faroe Islands are compatible with the assumption that their c.1222T allele is also associated with the same polymorphisms (data not shown).
Prevalence study
The novel AGL c.1222 C4T mutation was not detected in German newborns; in contrast, nine of 272 Faroese newborns were heterozygous (Table 2) . These numbers predict a carrier frequency of 1 : 30 and a prevalence of one GSD IIIA case per 3600 individuals (95% confidence interval 1:700 ± 1:6400).
Discussion
In this study we report the molecular basis of GSD IIIA in patients from the Faroe Islands. Based upon haplotype analysis, we speculate that due to a founder effect in the small isolated population of the islands a regional cluster has Table 1 Polymerase chain reaction primers used in this study for the formation of exon-specific amplimers and flanking intron regions of the AGL gene. PCR products were subject to direct sequencing and/or to mutation/polymorphism detection by mutation-or polymorphism-specific restriction enzyme digestion. Ref., denotes the first report of a polymorphism. Sense (sn) and antisense (asn) primers were chosen from the published sequence with lowercase and uppercase letters representing intron and exon sequences, respectively. An underlined letter represents a mismatch. T a , annealing temperature; RE, restriction enzyme. The haplotype associated with the c.1222T allele is highlighted in grey developed. The novel c.1222 C4T mutation could be detected in six children investigated, and it is most likely also responsible for previously reported cases. 3 It is interesting that also from the west coast of Norway where the Faroese population is supposed to have its origin, a cluster of GSD III cases has been reported 5 and it will be interesting to investigate the molecular basis of these cases. There is evidence that the novel nonsense mutation in exon 11 is disease-causing; it results in truncation of the gene product which should affect both enzymatic activities of the AGL protein, oligo-1,4-1,4-glucantransferase and amylo-1,6-glucosidase, due to the fact that the glycogen-binding site has been approximately located to a region encoded by exons 30 and 31. 6 Patients with less extensive carboxyterminal truncations have been shown to have characteristic clinical and biochemical features of GSD IIIA. 1 The c.1222 C4T mutation is not confined to the Faroe Islands, and our results show that it plays a role, albeit minor, world-wide. The c.1222T allele was found in approximately 2% of alleles of unselected GSD III cases. However, most AGL mutations are private and only four alleles (R864X, R1228X, c.3964 del T, and IVS32 ± 12 A4G) have been found in more than 5% of unselected GSD III cases. 1 We are currently aware of another eight cases of GSD IIIA in the Faroe Islands. This gives a total of 14 cases in a population of 45 000. From these figures, the observed prevalence of GSD IIIA in the Faroe Islands is 1 : 3100 which is within the same order of magnitude as 1 : 2000 (seven of 14 000) reported previously. 3 These numbers are in agreement with the prevalence determined by measuring allele frequencies in neonates. This method rendered a prevalence of 1 : 3600 which is more than 30 times higher than the prevalence in an unselected population. 7 It is the highest prevalence number for GSD IIIA world-wide, even when compared to another local cluster: for North African Jews in Israel a prevalence of 1 : 5400 for homozygosity for the c.4455 del T allele has been reported. 2 The detection of the molecular defect has facilitated the diagnosis of GSD IIIA in the Faroe Islands. For example, in one of the patients reported in this study, diagnosis on peripheral leukocyte DNA and the introduction of appropriate treatment were possible in the neonatal period obviating the need for a liver biopsy. Knowledge of the basic defect will offer a better basis for genetic counselling of couples at risk and for first trimester prenatal diagnosis by direct genomic analysis. This may cause prevalence rates to decline in populations such as that of the cluster region in Israel (S. Moses, personal communication). So far, however, none of the Faroese families have requested prenatal diagnosis. 
